Biotech's internal AI revolution reshapes talent acquisition

In biotech, 89% of scientists now use AI copilots or reasoning tools as their first stop for data interrogation, fundamentally changing their daily workflow. The widespread adoption of AI, with 89% of scientists using AI copilots or reasoning tools, reshapes research methods, establishing AI proficiency as a new baseline for discovery. The rapid integration of AI transforms biotech's hiring and talent acquisition strategies, compelling companies to rethink workforce development for 2026 and beyond.

Biotech scientists rapidly make AI their default interface for critical research tasks. However, the industry overwhelmingly develops its AI talent internally, rather than recruiting from the external tech sector. The industry's overwhelming internal development of AI talent, rather than external recruitment, creates tension between AI's immediate utility and the long-term potential for truly novel AI development within the sector.

Biotech companies investing heavily in upskilling their current scientific workforce in AI will likely gain significant advantage in innovation and talent retention. Those relying on external hires may struggle to integrate AI effectively. The internal cultivation of expertise, driven by heavy investment in upskilling the scientific workforce, defines a unique path for industry growth.

The Internal AI Revolution

• 67% — The top source of AI talent in biotech comes from internal upskilling, according to Benchling.
• 21% — AI talent is sourced from external tech hires, according to Benchling.

Biotech strategically cultivates AI expertise internally, transforming its scientific workforce into AI power users. Biotech's pervasive approach of strategically cultivating AI expertise internally, transforming its scientific workforce into AI power users, potentially limits novel AI development by not integrating diverse external AI perspectives.

Where AI is Making its Mark